img

Global Myelodysplastic Syndrome (MDS) Drugs Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Myelodysplastic Syndrome (MDS) Drugs Market Research Report 2024

Myelodysplastic syndrome is caused by mutation of one or more genes that control development of blood cells. It is one of the most common malignant hematological diseases that affects five out of every 100,000 people in U.S. annually. An estimated 60,000 people in U.S. live with MDS, and approximately 10,000-15,000 new cases are reported each year. Patients may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Exposure to chemicals (such as pesticides, tobacco, and benzene) and heavy metals (such as mercury and lead) may trigger disease onset.
According to MRAResearch’s new survey, global Myelodysplastic Syndrome (MDS) Drugs market is projected to reach US$ 2213.5 million in 2033, increasing from US$ 1454.3 million in 2022, with the CAGR of 5.7% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Myelodysplastic Syndrome (MDS) Drugs market research.
In recent years, demand for hypomethylating agents has been at a high due to approval and adoption of Vidaza and Dacogen. A strong pipeline including Aranesp is expected to boost market growth in the near future. Easy availability of and access to novel treatments in major countries provides strong commercial opportunities to the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Myelodysplastic Syndrome (MDS) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Celgene
Amgen
Otsuka
Takeda
Segment by Type
Hypomethylating Agents
Immunomodulatory Drugs
Anti-anemics

Segment by Application


Original
Generics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Myelodysplastic Syndrome (MDS) Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Hypomethylating Agents
1.2.3 Immunomodulatory Drugs
1.2.4 Anti-anemics
1.3 Market by Application
1.3.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Original
1.3.3 Generics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Perspective (2018-2033)
2.2 Myelodysplastic Syndrome (MDS) Drugs Growth Trends by Region
2.2.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Myelodysplastic Syndrome (MDS) Drugs Historic Market Size by Region (2018-2023)
2.2.3 Myelodysplastic Syndrome (MDS) Drugs Forecasted Market Size by Region (2024-2033)
2.3 Myelodysplastic Syndrome (MDS) Drugs Market Dynamics
2.3.1 Myelodysplastic Syndrome (MDS) Drugs Industry Trends
2.3.2 Myelodysplastic Syndrome (MDS) Drugs Market Drivers
2.3.3 Myelodysplastic Syndrome (MDS) Drugs Market Challenges
2.3.4 Myelodysplastic Syndrome (MDS) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome (MDS) Drugs Players by Revenue
3.1.1 Global Top Myelodysplastic Syndrome (MDS) Drugs Players by Revenue (2018-2023)
3.1.2 Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Myelodysplastic Syndrome (MDS) Drugs Revenue
3.4 Global Myelodysplastic Syndrome (MDS) Drugs Market Concentration Ratio
3.4.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome (MDS) Drugs Revenue in 2022
3.5 Myelodysplastic Syndrome (MDS) Drugs Key Players Head office and Area Served
3.6 Key Players Myelodysplastic Syndrome (MDS) Drugs Product Solution and Service
3.7 Date of Enter into Myelodysplastic Syndrome (MDS) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myelodysplastic Syndrome (MDS) Drugs Breakdown Data by Type
4.1 Global Myelodysplastic Syndrome (MDS) Drugs Historic Market Size by Type (2018-2023)
4.2 Global Myelodysplastic Syndrome (MDS) Drugs Forecasted Market Size by Type (2024-2033)
5 Myelodysplastic Syndrome (MDS) Drugs Breakdown Data by Application
5.1 Global Myelodysplastic Syndrome (MDS) Drugs Historic Market Size by Application (2018-2023)
5.2 Global Myelodysplastic Syndrome (MDS) Drugs Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Myelodysplastic Syndrome (MDS) Drugs Market Size (2018-2033)
6.2 North America Myelodysplastic Syndrome (MDS) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2018-2023)
6.4 North America Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Myelodysplastic Syndrome (MDS) Drugs Market Size (2018-2033)
7.2 Europe Myelodysplastic Syndrome (MDS) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2018-2023)
7.4 Europe Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Size (2018-2033)
8.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Myelodysplastic Syndrome (MDS) Drugs Market Size (2018-2033)
9.2 Latin America Myelodysplastic Syndrome (MDS) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2018-2023)
9.4 Latin America Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myelodysplastic Syndrome (MDS) Drugs Market Size (2018-2033)
10.2 Middle East & Africa Myelodysplastic Syndrome (MDS) Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Celgene
11.1.1 Celgene Company Detail
11.1.2 Celgene Business Overview
11.1.3 Celgene Myelodysplastic Syndrome (MDS) Drugs Introduction
11.1.4 Celgene Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023)
11.1.5 Celgene Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Myelodysplastic Syndrome (MDS) Drugs Introduction
11.2.4 Amgen Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023)
11.2.5 Amgen Recent Development
11.3 Otsuka
11.3.1 Otsuka Company Detail
11.3.2 Otsuka Business Overview
11.3.3 Otsuka Myelodysplastic Syndrome (MDS) Drugs Introduction
11.3.4 Otsuka Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023)
11.3.5 Otsuka Recent Development
11.4 Takeda
11.4.1 Takeda Company Detail
11.4.2 Takeda Business Overview
11.4.3 Takeda Myelodysplastic Syndrome (MDS) Drugs Introduction
11.4.4 Takeda Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023)
11.4.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Hypomethylating Agents
Table 3. Key Players of Immunomodulatory Drugs
Table 4. Key Players of Anti-anemics
Table 5. Global Myelodysplastic Syndrome (MDS) Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Region (2018-2023)
Table 9. Global Myelodysplastic Syndrome (MDS) Drugs Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 10. Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Region (2024-2033)
Table 11. Myelodysplastic Syndrome (MDS) Drugs Market Trends
Table 12. Myelodysplastic Syndrome (MDS) Drugs Market Drivers
Table 13. Myelodysplastic Syndrome (MDS) Drugs Market Challenges
Table 14. Myelodysplastic Syndrome (MDS) Drugs Market Restraints
Table 15. Global Myelodysplastic Syndrome (MDS) Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Players (2018-2023)
Table 17. Global Top Myelodysplastic Syndrome (MDS) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome (MDS) Drugs as of 2022)
Table 18. Ranking of Global Top Myelodysplastic Syndrome (MDS) Drugs Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Myelodysplastic Syndrome (MDS) Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Myelodysplastic Syndrome (MDS) Drugs Product Solution and Service
Table 22. Date of Enter into Myelodysplastic Syndrome (MDS) Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Type (2018-2023)
Table 26. Global Myelodysplastic Syndrome (MDS) Drugs Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 27. Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Type (2024-2033)
Table 28. Global Myelodysplastic Syndrome (MDS) Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Application (2018-2023)
Table 30. Global Myelodysplastic Syndrome (MDS) Drugs Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 31. Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Application (2024-2033)
Table 32. North America Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 33. North America Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2024-2033) & (US$ Million)
Table 35. Europe Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. Europe Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2024-2033) & (US$ Million)
Table 38. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 39. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Size by Region (2024-2033) & (US$ Million)
Table 41. Latin America Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 42. Latin America Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2024-2033) & (US$ Million)
Table 44. Middle East & Africa Myelodysplastic Syndrome (MDS) Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 45. Middle East & Africa Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Myelodysplastic Syndrome (MDS) Drugs Market Size by Country (2024-2033) & (US$ Million)
Table 47. Celgene Company Detail
Table 48. Celgene Business Overview
Table 49. Celgene Myelodysplastic Syndrome (MDS) Drugs Product
Table 50. Celgene Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023) & (US$ Million)
Table 51. Celgene Recent Development
Table 52. Amgen Company Detail
Table 53. Amgen Business Overview
Table 54. Amgen Myelodysplastic Syndrome (MDS) Drugs Product
Table 55. Amgen Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023) & (US$ Million)
Table 56. Amgen Recent Development
Table 57. Otsuka Company Detail
Table 58. Otsuka Business Overview
Table 59. Otsuka Myelodysplastic Syndrome (MDS) Drugs Product
Table 60. Otsuka Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023) & (US$ Million)
Table 61. Otsuka Recent Development
Table 62. Takeda Company Detail
Table 63. Takeda Business Overview
Table 64. Takeda Myelodysplastic Syndrome (MDS) Drugs Product
Table 65. Takeda Revenue in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023) & (US$ Million)
Table 66. Takeda Recent Development
Table 67. Research Programs/Design for This Report
Table 68. Key Data Information from Secondary Sources
Table 69. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myelodysplastic Syndrome (MDS) Drugs Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Type: 2022 VS 2033
Figure 3. Hypomethylating Agents Features
Figure 4. Immunomodulatory Drugs Features
Figure 5. Anti-anemics Features
Figure 6. Global Myelodysplastic Syndrome (MDS) Drugs Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 7. Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Application: 2022 VS 2033
Figure 8. Original Case Studies
Figure 9. Generics Case Studies
Figure 10. Myelodysplastic Syndrome (MDS) Drugs Report Years Considered
Figure 11. Global Myelodysplastic Syndrome (MDS) Drugs Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Myelodysplastic Syndrome (MDS) Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Region: 2022 VS 2033
Figure 14. Global Myelodysplastic Syndrome (MDS) Drugs Market Share by Players in 2022
Figure 15. Global Top Myelodysplastic Syndrome (MDS) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome (MDS) Drugs as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Myelodysplastic Syndrome (MDS) Drugs Revenue in 2022
Figure 17. North America Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Myelodysplastic Syndrome (MDS) Drugs Market Share by Country (2018-2033)
Figure 19. United States Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Myelodysplastic Syndrome (MDS) Drugs Market Share by Country (2018-2033)
Figure 23. Germany Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Share by Region (2018-2033)
Figure 31. China Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Myelodysplastic Syndrome (MDS) Drugs Market Share by Country (2018-2033)
Figure 39. Mexico Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Myelodysplastic Syndrome (MDS) Drugs Market Share by Country (2018-2033)
Figure 43. Turkey Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia Myelodysplastic Syndrome (MDS) Drugs Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Celgene Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023)
Figure 46. Amgen Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023)
Figure 47. Otsuka Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023)
Figure 48. Takeda Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Drugs Business (2018-2023)
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries